The liver is the central metabolic organ of the human body, responsible for over 500 distinct biochemical functions — including the metabolism of carbohydrates, fats, and proteins, the detoxification of drugs and xenobiotics, the synthesis of plasma proteins and clotting factors, the storage of glycogen and fat-soluble vitamins, and the regulation of the blood glucose and the blood lipid levels. When the liver accumulates fat (as it does in the non-alcoholic fatty liver disease that affects an estimated 25-30% of the global adult population), its metabolic functions are impaired, its capacity to detoxify blood is reduced, and its ability to regulate the blood glucose and the blood lipid levels is compromised. The progression from simple liver steatosis (fatty liver) to steatohepatitis (NASH, the inflammatory form of fatty liver disease) to fibrosis and ultimately to cirrhosis reflects a cascade of mitochondrial dysfunction, oxidative stress, and inflammatory cytokine activation that destroys the hepatic architecture and impairs the liver regenerative capacity. HepatoBurn is a supplement that was formulated to address the root cause of fatty liver disease — the mitochondrial dysfunction that prevents the liver from oxidising the fat that it has accumulated — combining seven superingredients that target each of the major mechanisms of hepatic mitochondrial dysfunction.
The Mitochondrial Dysfunction of Fatty Liver Disease
The mitochondria are the cellular power plants that generate ATP through the oxidative phosphorylation of the NADH and the FADH2 that are produced by the metabolism of glucose, fatty acids, and amino acids. In the fatty liver, the mitochondria are overloaded with fat (because the liver is processing and storing more fat than it can oxidise), and this fat overload produces a cascade of mitochondrial dysfunction — the electron transport chain becomes inefficient, the proton gradient leaks, the ROS production increases, the mitochondrial DNA is damaged, and the capacity to generate ATP is progressively reduced. This mitochondrial dysfunction is the primary driver of the metabolic impairment that characterises the fatty liver — when the mitochondria cannot generate ATP efficiently, the liver cannot perform its metabolic functions, and the metabolic dysregulation that underlies the metabolic syndrome and the type 2 diabetes develops. The restoration of the mitochondrial function in the liver is therefore one of the most important therapeutic targets for the reversal of fatty liver disease, and it is the primary mechanism of action of the HepatoBurn formulation.
The L-carnitine is one of the most important ingredients in the HepatoBurn formulation for the restoration of the hepatic mitochondrial function — it is the essential cofactor for the transport of the long-chain fatty acids into the mitochondrial matrix, where they are oxidised by the beta-oxidation enzymes. Without adequate L-carnitine, the fatty acids cannot enter the mitochondria, they accumulate in the hepatocyte cytoplasm as triglycerides, and the hepatic fat content increases. Multiple clinical trials have demonstrated that L-carnitine supplementation reduces the liver fat content, improves the liver enzyme levels, and enhances the insulin sensitivity in people with NAFLD — the proposed mechanism involves the restoration of the fatty acid oxidation in the hepatic mitochondria and the reduction of the hepatic fat content through the enhanced oxidation of the stored triglycerides.
The R-Alpha Lipoic Acid and the Insulin Sensitisation Mechanism
The R-alpha-lipoic acid (R-ALA) is the natural form of alpha-lipoic acid (the synthetic form is a 50/50 mixture of the R and S enantiomers), and it is a more potent antioxidant and a more effective insulin sensitiser than the S form. R-ALA has been shown in multiple clinical trials to improve the insulin sensitivity, to reduce the fasting blood glucose, to reduce the HbA1c, and to improve the liver function in people with type 2 diabetes and with insulin resistance — the proposed mechanism involves the activation of the AMPK enzyme (which is the master regulator of cellular energy metabolism), the enhancement of the GLUT4 translocation to the cell membrane (which increases the insulin-independent glucose uptake), and the reduction of the oxidative stress and the inflammation that are the primary drivers of the insulin resistance. The insulin sensitising effect of R-ALA is particularly important for the management of fatty liver disease because insulin resistance is both a cause and a consequence of hepatic fat accumulation — when the insulin receptors in the liver are resistant to insulin, the liver continues to produce glucose and to store fat even when the blood insulin levels are elevated, and this drives the further accumulation of fat in the liver.
Real-World Results and Who Should Use HepatoBurn
HepatoBurn is designed for adults who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) or with the metabolic risk factors that are associated with fatty liver disease — including central obesity, type 2 diabetes, insulin resistance, high triglycerides, and low HDL cholesterol. It is also appropriate for people who have elevated liver enzyme levels (ALT, AST, GGT) on blood tests and who want to reduce the risk of the progression from simple steatosis to steatohepatitis and to fibrosis. HepatoBurn is not intended for people with advanced cirrhosis or with acute liver failure, and it should not be used as a substitute for the medical management of these serious liver conditions. People who are taking prescription medications that affect liver function should discuss the use of HepatoBurn with their healthcare provider before starting supplementation.
Practical Application
The recommended dose of HepatoBurn is two capsules taken daily with a meal, which provides the equivalent of 1,000mg of L-carnitine (as L-carnitine L-tartrate, which is more bioavailable than the basic L-carnitine form), 300mg of R-alpha-lipoic acid (as the sodium salt form, which is more stable and better absorbed than the free acid form), 500mg of milk thistle extract (standardised to 80% silymarin), 300mg of N-acetylcysteine (NAC, which provides the cysteine that is required for the synthesis of glutathione), 200mg of selenium (as selenomethionine, which is the organic form that is better absorbed than the inorganic selenite), and 100mg of alpha-tocopherol (vitamin E). For best results, HepatoBurn should be taken consistently for at least 12-16 weeks, as the restoration of the hepatic mitochondrial function and the reduction of the liver fat content take time to develop. HepatoBurn pairs well with the Mediterranean dietary pattern (which is associated with reduced liver fat content and with improved hepatic insulin sensitivity), with the regular aerobic exercise programme (which increases the hepatic mitochondrial fat-burning capacity), and with the reduction of alcohol consumption (which removes one of the major sources of hepatic oxidative stress and of liver fat accumulation).
Leave a Reply